Symptomatic hypomagnesemia in cystic fibrosis

Green, Christopher G.; Doershuk, Carl F.; Stern, Robert C.

doi:10.1016/s0022-3476(85)80526-6

Cited by 23 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chance‐adjusted agreement between the two investigators on the application of the inclusion and exclusion criteria was 0.88. Twenty‐five original scientific reports published in English between 1964 and 2012 were retained for the final analysis, as depicted in Figure . They had been reported from the following countries: United States of America (N = 8), United Kingdom (N = 5), Germany (N = 3), Ireland (N = 2), Switzerland (N = 2), Australia (N = 1), Belgium (N = 1), Brazil (N = 1), Israel (N = 1), and Sweden (N = 1).…”

Section: Resultsmentioning

confidence: 99%

Magnesium in cystic fibrosis—Systematic review of the literature

Santi¹,

Milani

Simonetti

et al. 2015

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Magnesium in cystic fibrosis—Systematic review of the literature

Santi¹,

Milani

Simonetti

et al. 2015

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Symptomatic hypomagnesaemia associated with aminoglycosides in CF is well documented 16. Holben et al described a series of 192 patients with CF with a prevalence of hypomagnesaemia of 3% 17…”

Section: Renal Toxicity In Cystic Fibrosismentioning

confidence: 99%

Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis

Prayle

Watson

Fortnum

et al. 2010

Thorax

129

View full text Add to dashboard Cite

Aminoglycoside antibiotics are a central component of the treatment of pulmonary exacerbations of cystic fibrosis (CF) and slow the decline in lung function which ultimately causes the death of most patients. The prognosis of CF has improved, and thus side effects of treatments have become increasingly important. Observational studies suggest that the morbidity from side effects of aminoglycosides is disturbingly common, and that aggressive treatment may lead to more side effects. This review of the current literature on side effects of aminoglycosides considers the pathophysiological mechanisms, epidemiology and risk factors, investigation of side effects and preventative strategies. Treatments which have shown early promise are identified and areas of future research are discussed.

show abstract

“…Typical manifestations of ototoxicity such as loss of hair cells and degeneration of ganglion cells have been reported in CF patients [117,118]. This may lead to high tone deafness and hypokalaemia or hypomagnesaemia [119]. Acute vestibular toxicity may be seen if the drug is given rapidly [102] and a long infusion is preferable.…”

Section: Intravenous Antipseudomonal Antibiotic Therapy In Cystic Fibmentioning

confidence: 99%

“…Acute vestibular toxicity may be seen if the drug is given rapidly [102] and a long infusion is preferable. Some studies suggest tobramycin may be less nephrotoxic than gentamicin [119]. Administration of 15 mg .…”

Section: Intravenous Antipseudomonal Antibiotic Therapy In Cystic Fibmentioning

confidence: 99%

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Döring¹,

Conway²,

Heijerman³

et al. 2000

Eur Respir J

556

478

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity in caucasians. The majority of CF patients suffer from chronic respiratory infection with the opportunistic bacterial pathogen Pseudomonas aeruginosa. No consensus among clinicians has been reached so far concerning antibiotic treatment against P. aeruginosa in CF patients.Consensus answers to 24 important questions in this context, based on current evidence, are presented, given by a panel of 34 European experts. Questions addressed and answered are: The diagnosis of P. aeruginosa lung colonization in CF; The impact of P. aeruginosa on the clinical state of CF patients; The assessment of P. aeruginosa susceptibility against antibiotics and the importance of these results for the clinician; The use of monotherapy versus combination therapy; The development of microbial resistance; The achievement of optimal airway concentrations; The effects of subinhibitory concentrations of antibiotics on P. aeruginosa; Statements on the pharmacokinetics of antibiotics in CF patients; Recommendations for doses and dosing intervals and length of treatment regimens; and Toxic side effects due to repeated antibiotic therapy was addressed.The expert panel answered further questions on the use of fluoroquinolones in children with CF, on the administration of nebulized antibiotics and whether prevention of P. aeruginosa lung colonization is possible in CF using antibiotic therapy.Problems of antibiotic therapy at home and in the hospital were addressed, a consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations.Finally, the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in cystic fibrosis patients were addressed and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended. Eur Respir J 2000; 16: 749±767.

show abstract

Symptomatic hypomagnesemia in cystic fibrosis

Cited by 23 publications

References 9 publications

Magnesium in cystic fibrosis—Systematic review of the literature

Magnesium in cystic fibrosis—Systematic review of the literature

Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Contact Info

Product

Resources

About